

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF CSTONE IN THE HONG KONG STOCK CONNECT

This announcement is made by CStone Pharmaceuticals (the “**Company**” or “**CStone**” and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the shares of the Company had been included in the Hong Kong Stock Connect with effect from September 6, 2021, indicating eligible domestic investors can now directly trade the Company’s shares through the Hong Kong Stock Connect.

Dr. Frank Jiang, Chairman and CEO of CStone said, “The inclusion of CStone in the Hong Kong Stock Connect reflects the recognition of our capabilities and value from the investor community. We expect that the inclusion can allow us to access a broader investor base in Mainland China. CStone is committed to providing innovative therapies to meet the urgent medical needs of cancer patients in Mainland China and worldwide. In the future, we will continue to provide breakthrough therapies to cancer patients for longer and healthier lives.”

In the first half of 2021, CStone has successfully launched two first-in-class (“**FIC**”) oncology precision products GAVRETO[®] and AYVAKIT[®] and achieved remarkable sales. Additionally, the Company has submitted four new drug applications (“**NDA**”), among which two FIC/potential best-in-class (“**BIC**”) products, ivosedinib and sugemalimab, will soon be approved. This demonstrates CStone’s strong research, development and commercialization capabilities. In 2022, the Company expects to file more than five NDAs, further enhancing the research and development of innovative drugs, and submit one to two investigational new drug applications for our highly differentiated molecules with FIC/BIC/first-wave potential and global rights, harnessing the full potential of Pipeline 2.0 while unleashing the potential of our product portfolio globally.

About CStone

CStone is a biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in

Mainland China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan, China, and multiple late-stage candidates are in pivotal trials or registrational stages. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By Order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Suzhou, the People's Republic of China, September 6, 2021

As at the date of this announcement, the Board comprises Dr. Frank Ningjun Jiang as Chairman and executive director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.